Abstract. The etiology of laryngeal squamous cell carcinoma (LSCC) has not yet been adequately examined. Therefore, the present study aimed to investigate the association between serum folate deficiency and abnormal expression of the cell adhesion molecule 1 (CADM1) protein in the progression of LSCC. Samples were collected from 60 patients with LSCC and 30 healthy people. Radioimmunoassays and immunohistochemical staining were performed to measure serum folate levels and CADM1 protein expression, respectively. The results demonstrated that CADM1 expression in LSCC specimens was significantly lower than in adjacent normal tissues ($\chi^2=28.229$, $P<0.001$), which was associated with histological differentiation and clinical stage ($P=0.010$ and 0.020, respectively). Levels of serum folate in patients with LSCC were significantly lower than those observed in healthy individuals ($P=0.002$). Furthermore, TSLC1 expression and serum folate levels were positively correlated in LSCC ($r=0.642$, $P=0.001$). Thus, the present study determined that decreased CADM1 protein expression and low levels of serum folate were correlated with an increased severity of LSCC.

Introduction

Laryngeal squamous cell carcinoma (LSCC) is one of the most common malignant tumors identified in the head and neck. LSCCs account for 90% of all larynx carcinomas, ~90% of which are in males. Furthermore, the majority of patients are aged between 40 and 60-years-old (1). At present, there is no specific biomarker for LSCC diagnosis and prognosis. Thus, the current study aimed to examine potential biomarkers that could improve the early diagnosis of LSCC.

The cell adhesion molecule 1 (CADM1) gene encodes a membrane protein, which is silenced in ~44% of patients with non-small cell lung cancer and 30-60% of those with other types of cancer (2). Previous studies have identified two mechanisms of CADM1 inactivation: Promoter hypermethylation and loss of heterozygosity (3-5). Furthermore, it has been demonstrated that the CADM1 protein participates in a number of biological functions, including synapse formation, cell adhesion and tumor suppression (6). In several types of tumors, the absence of CADM1 expression is closely related to invasive tumor behavior (6-9). However, the role of CADM1 in LSCC remains largely unknown. To investigate the association between CADM1 protein expression and the development of LSCC, 60 surgically resected specimens were collected and assessed for loss of the CADM1 protein using immunohistochemistry. Subsequently, the association of CADM1 protein expression with LSCC clinicopathological parameters and the histological growth pattern of the tumors were investigated.

Folate is a water-soluble B vitamin that mediates one-carbon metabolism in vivo and serves multiple functions in physiological processes. Folate provides one-carbon groups for DNA replication, epigenetic modifications and DNA mutation prevention, thus protecting against tumorigenesis (10). Additionally, tetrahydrofolate synthesis in vivo requires folate for blood cell development and maturation (11). Folate deficiency is closely associated with glossitis, anemia and, in pregnancy, fetal neural tube defects (12). Previous studies have suggested that folate may aid cancer prevention (13,14), and several studies have demonstrated that a reduction in serum folate levels may be closely related to several types of cancer, including colorectal cancer (15-17). However, no similar report in LSCC was found in the literature. Therefore, it is necessary to investigate the relationship between serum folate levels and...
cancer progression and prognosis. The present study aimed to investigate the underlying association between folate deficiency and CADM1 protein expression in LSCC.

**Patients and methods**

**Patients and tissue specimens.** A total of 60 pairs of LSCC and precancerous specimens were collected from patients treated at the Department of Otolaryngology, Head and Neck Surgery at the First Affiliated Hospital of Henan University of Science and Technology (Luoyang, China) between September 2011 and September 2014. The control group consisted of 30 healthy volunteers whose blood was collected during routine health examinations. The ratio of patients to healthy volunteers was 1:2. Precancerous tissues were defined as the laryngeal mucosa 2 cm from the edge of the cancerous site. Patients had undergone preoperative partial or total laryngectomy without radical and chemical therapies. Patients with megaloblastic anemia or other types of anemia, upper gastrointestinal tract diseases, and those treated with any other surgical procedures, were excluded. Patients with a history of smoking, oral contraceptive use or those who had taken B vitamins in the past 6 months were also excluded from the current study. The Ethics Committee of the First Affiliated Hospital of Henan University of Science and Technology (Luoyang, China) approved the use of human tissues for the current study. All patients and volunteers provided written informed consent to participate.

**Immunohistochemistry.** Expression of the CADM1 protein was tested using an Immunohistochemical S-P kit against CADM1 (Kangwei Bio, Ltd., Beijing, China), according to the manufacturer's protocol. A rabbit polyclonal antibody against CADM1 (1:100 dilution, cat. no. Rs-1147R) was purchased from Kangwei Bio, Ltd. Tissues were fixed with 10% formaldehyde solution, cut into 3-µm sections, embedded in paraffin blocks and subsequently incubated with the polyclonal antibody at 4˚C overnight (>14 h). Sections were subsequently incubated with biotinylated goat anti-rabbit immunoglobulin G (1:100 dilution, cat. no. CW2035S; Kangwei Bio, Ltd.) for 40 min at room temperature. Phosphate-buffered saline was incubated with biotinylated goat anti-rabbit immunoglobulin G (1:100 dilution, cat. no. CW2035S; Kangwei Bio, Ltd.) for 40 min at room temperature. Phosphate-buffered saline was used as a negative control. 3,3'-diaminobenzidine was used to stain the sections and hematoxylin was used as a counterstain to highlight the cytotoblasts and background color. Each section was observed in 10 random fields under x200 magnification (18). The score was calculated by adding the scores for intensity (weak=1, moderate=2, intense=3) and proportion (5%=-1, 6-24%=2, 25-49%=3, 50-74%=4, ≥75%=5) of positively stained cells (19). Scores of ≥2 were considered positive. Two independent pathologists assessed each slide.

**Radioimmunoassay.** Whole blood samples (6 ml) were drawn from a peripheral vein of each participant after overnight fasting. Following the centrifugation of whole blood samples at 300 x g for 15 min, serum samples were collected and stored at -80°C until analysis. Serum folate levels were tested using radioimmunoassay quantification with a commercial kit for measurement of folate (Shanghai Ruiqi Bio-Technology, Co., Ltd., Shanghai, China), according to the manufacturer's instructions.

**Statistical analysis.** Data were analyzed using Student's t-test, χ² test, one-way analysis of variance (ANOVA), Student-Newman-Keuls test, Fisher's exact test and Spearman's rank correlation coefficient. SPSS version 16.0 for Windows (SPSS Inc., Chicago, IL, USA) was used to analyze all results. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Expression of the CADM1 protein in LSCC.** CADM1 protein expression was detected via immunohistochemical analysis of 60 malignant squamous cells of larynx tumors and 60 corresponding healthy adjacent non-neoplastic tissues, which were examined as a comparison. The results demonstrated that 47 specimens (78%) of adjacent normal tissues expressed CADM1 protein. By contrast, only 12 tumor specimens (20%) expressed the CADM1 protein (P<0.001; Table I). The associations among CADM1 expression patterns in the tumors, serum folate levels and patient clinical characteristics are presented in Table II. Positive staining indicated that CADM1 was primarily located in the cytoplasm in the adjacent normal tissues, but was absent in the tumor tissues (Fig. 1A and B, indicated by shapes). Expression of the CADM1 protein was not correlated with patient age or anatomic localization (P=1.000 and 0.386, respectively), but was correlated with histological differentiation and clinical stage (P=0.010 and 0.020, respectively; Table II).

**Associations among patient characteristics, expression of CADM1 and serum folate levels.** One-way ANOVA was used to determine differences in the serum folate levels among LSCC tissues with different clinical characteristics, including age, clinical stage, histological differentiation and anatomic localization. The differences were statistically significant among tumor tissues with different clinical stages, histological differentiation and anatomic localization. The results indicated that serum folate levels decreased as tumor malignancy increased (Table III). Additionally, serum folate levels were significantly lower in patients with LSCC compared with healthy control subjects (P=0.002; Table IV). The spearman correlation analysis identified a
significant correlation between CADM1 protein expression and serum folate levels (r=0.642, P=0.001). Therefore, folate deficiency may decrease the methylation of CADM1 promoter and regulate CADM1 expression. However, further studies are required to confirm this.

**Discussion**

In the present study, all included patients were male and most patients aged <50 years were TNM stage III or IV with higher serum folate levels, whereas patients aged >50 years were stages I-II with lower serum folate levels. The critical factor in the prognosis of LSCC is tumor metastasis, however, the etiopathogenesis of tumor metastasis remains largely unknown and may involve immune dysregulation. CADM1, located on chromosome 11q23.2, encodes a transmembrane protein from the immunoglobulin superfamily (20). Previous studies have demonstrated that CADM1 is a human tumor suppressor and mutations in its cytoplasmic domain have been linked to lung tumor cell metastasis, aggravated histological differentiation, clinical stage classification and a poor prognosis (6,21,22). The results of the present study were consistent with previous studies (23,24) and established that, as compared with adjacent non-neoplastic tissue, tumor tissues express lower levels of CADM1. This is important as CADM1 may serve a potential role in the diagnosis and prognosis of LSCC.

Duthie et al (25) affirmed the effect of folate deficiency on chromosome breaks and the risk of carcinogenesis. Furthermore, it has been determined that folate deficiency

---

**Table II. Associations among patient clinical characteristics, protein expression of CADM1 and serum folate levels.**

| Characteristic               | n    | P   | N   | Folic acid (ng/ml) | P-value: Fisher's exact test | P-value: One-way ANOVA |
|-----------------------------|------|-----|-----|--------------------|------------------------------|------------------------|
| Age (years)                 |      |     |     |                    |                              |                        |
| ≥50                         | 49   | 15  | 34  | 3.53±1.53          |                              |                        |
| <50                         | 11   | 3   | 8   | 2.36±0.98          | 1.000                        | 0.058                  |
| TNM stage                   |      |     |     |                    |                              |                        |
| I                           | 27   | 12  | 15  | 3.69±1.45          |                              |                        |
| II                          | 17   | 6   | 11  | 3.65±1.57          |                              |                        |
| III                         | 11   | 0   | 11  | 2.44±1.32          |                              |                        |
| IV                          | 5    | 0   | 5   | 2.46±1.07          | 0.010                       | 0.001^b                |
| Histological differentiation|      |     |     |                    |                              |                        |
| Well                        | 34   | 15  | 19  | 3.85±1.33          |                              |                        |
| Moderately                  | 16   | 3   | 13  | 3.18±1.66          |                              |                        |
| Poorly                      | 10   | 0   | 10  | 1.95±0.86          | 0.010                       | 0.001^b                |
| Anatomic localization       |      |     |     |                    |                              |                        |
| Supraglottic                | 8    | 2   | 6   | 2.08±0.96          |                              |                        |
| Glottic                     | 39   | 14  | 25  | 3.86±1.45          |                              |                        |
| Subglottic                  | 13   | 2   | 11  | 2.94±1.23          | 0.386                        | 0.001^b                |

^aP<0.05; ^bP<0.01; n, number of patients; P, CADM1-positive cells; N, CADM1-negative cells; CADM1, cell adhesion molecule 1; ANOVA, analysis of variance; TNM, tumor-node-metastasis.

---

![Figure 1. Cell adhesion molecule 1 (CADM1) expression in laryngeal squamous cell carcinoma tumor tissue compared with adjacent normal tissue. (A) CADM1 expression in severe atypical hyperplasia tissue and the absence of its expression in the tumor (magnification, x100). ▲ = Severe atypical hyperplasia tissue, ● = tumor tissue. (B) CADM1 expression in mild atypical hyperplasia tissue and the absence of its expression in the tumor (magnification, x100). ▲ = Mild atypical hyperplasia tissue. ● = tumor tissue.](image)
Effect of maternal and postweaning folic acid: Analysis of.

- Decreased. Therefore, folate deficiency may be associated with the increased energy needs of patients with cancer)

- Serum folate levels in patients with LSCC were markedly lower than those in healthy controls. Furthermore, tumor tissue. It was observed that a significant proportion under the underlying mechanism was not investigated. Therefore, further clinical studies are necessary. In future studies, we intend to evaluate the effectiveness of serum folic acid supplementation in patients with LSCC and to identify the intrinsic relationship between folate and promoter methylation of the CADM1 gene.

Acknowledgements

This study was supported by the Provincial Science and Technology Foundation of Henan Province, China (grant no. 132102310029).

References

1. Huang XZ, Wang JB and Kong WJ: Practice of Otorhinolaryngology-Head and Neck Surgery. 2nd edition. People's Medical Publishing House, Bei Jing, China, 2007.

2. Murakami Y, Nobukuni T, Tamura K, Maruyama T, Sekiya T, Arai Y, Gomyou H, Tanigami A, Ohki M, Cabin D, et al: Localization of tumor suppressor activity important in nonsmall cell lung carcinoma on chromosome 11q. Proc Natl Acad Sci USA 95: 8153-8158, 1998.

3. Allinen M, Peri L, Kuja J, Lahti-Domenski J, Outila K, Kapprinin SM, Launonen V and Winquist R: Analysis of 11q21-24 loss of heterozygosity candidate target genes in breast cancer: Indications of TSLC1 promoter hypermethylation. Genes Chromosomes Cancer 34: 384-389, 2002.

4. Fong KM, Kida Y, Zimmerman PV, Ikenaga M and Smith PJ: Loss of heterozygosity frequently affects chromosome 17q in non-small cell lung cancer. Cancer Res 55: 4268-4272, 1995.

5. Zhou L, Jiang W, Ren C, Yin Z, Feng X, Liu W, Tao Q and Yao K: Frequent hypermethylation of RASSF1A and TSLC1 and high viral load of Epstein-Barr Virus DNA in nasopharyngeal carcinoma and matched tumor-adjacent tissues. Neoplasia 7: 809-815, 2005.

6. Kuramochi M, Fukuhara H, Nobukuni T, Kanne T, Maruyama T, Ghosh HP, Pletcher M, Isomura M, Onizuka M, Kitamura T, et al: TSLC1 is a tumor suppressor gene in human non-small cell lung cancer. Nat Genet 27: 427-430, 2001.

7. Murakami Y: Involvement of a cell adhesion molecule, TSLC1/IGSF4, in human oncogenesis. Cancer Sci 96: 543-553, 2005.

8. Fukuhara H, Kuramochi M, Fukami T, Kasahara K, Furuhata M, Nobukuni T, Maruyama T, Isogai K, Sekiya T, Shuin T, et al: Promoter methylation of TSLC1 and tumor suppression by its gene product in human prostate cancer. Jpn J Cancer Res 93: 605-609, 2002.

9. Jansen M, Fukushima N, Rosty C, Walter K, Althick R, Heek TV, Huban R, Offerhaus JG and Goggins M: Aberrant methylation of the 5' CpG island of TSLC1 is common in pancreatic ductal adenocarcinoma and is first manifest in high-grade PanINs. Cancer Biol Ther 1: 293-296, 2002.

10. Kamen B: Folate and antifolate pharmacology. Semin Oncol 24 (Suppl 18): S18-30-S18-39, 1997.

11. Friso S and Choi SW: Gene-nutrient interactions and DNA methylation. J Nutr 132 (8 Suppl): 2382S-2387S, 2002.

12. Allen RH, Stabler SP, Savage DG and Lindenbaum J: Metabolic abnormalities in cobalamin (vitamin B12) and folate deficiency. FASEB J 7: 1344-1353, 1993.

13. Sie KK, Medline A, van Weel J, Sohn KJ, Choi SW, Croxford R and Kim YI: Effect of maternal and postweaning folic acid supplementation on colorectal cancer risk in the offspring. Gut 60: 1687-1694, 2011.

14. Jennings BA and Willis G: How folate metabolism affects colorectal cancer development and treatment; a story of heterogeneity and pleiotropy. Cancer Lett 356: 224-230, 2015.
15. Kim YI: Role of folate in colon cancer development and progression. J Nutr 133 (11 Suppl): 3731S-3739S, 2003.
16. Choi SW and Mason JB: Folate status: Effects on pathways of colorectal carcinogenesis. J Nutr 132 (8 Suppl): 2413S-2418S, 2002.
17. Kim YI: Folate and carcinogenesis: Evidence, mechanisms, and implications. J Nutr Biochem 10: 66-88, 1999.
18. Kuramochi M, Fukuhara H, Nobukuni T, Kanbe T, Maruyama T, Ghosh HP, Fletcher M, Isomura M, Onizuka M, Kitamura T, et al: TSLC1 is a tumor-suppressor gene in human non-small-cell lung cancer. Nat Genet 27: 427-430, 2001.
19. Yong M, Yang L, Suyila Q, Han W, Yuan H, Zhao C and Su X: Expression and clinical implications of P53, P63, and P73 protein in malignant tumor of the parotid gland. Turk J Med Sci 44: 875-882, 2014.
20. Yurdakul A, Akyurek N, Yilmaz S, Karakaya J, Memis L and Ozturk C: Prognostic impact of matrix metalloproteinases (MMP-9 and MMP-2) and vascular endothelial growth factor expression in non-small cell lung cancer. Turk J Med Sci 42: 281-288, 2012.
21. Uchino K, Ito A, Wakayama T, Koma Y, Okada T, Obayashi C, Iseki S, Kitamura Y, Tsukuba N, Okita Y and Okada M: Clinical implication and prognostic significance of the tumor suppressor TSLC1 gene detected in adenocarcinoma of the lung. Cancer 98: 1002-1007, 2003.
22. Blount BC, Mack MM, Wehr CM, MacGregor JT, Hiatt RA, Wang G, Wickrainsinghe SN, Everson RB and Ames BN: Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: Implications for cancer and neuronal damage. Proc Natl Acad Sci USA 94: 3290-3295, 1997.
23. Surace EI, Lusis E, Murakami Y, Scheithauer BW, Perry A and Gutmann DH: Loss of tumor suppressor in lung cancer-1 (TSLC1) expression in meningioma correlates with increased malignancy grade and reduced patient survival. J Neuropathol Exp Neurol 63: 1015-1027, 2004.
24. Steenbergen RD, Kramer D, Braakhuis BJ, Stern PL, Verheijen RH, Meijer CJ and Snijders PJ: TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia. J Natl Cancer Inst 96: 294-305, 2004.
25. Duthie SJ, Grant G and Narayanan S: Increased uracil misincorporation in lymphocytes from folate-deficient rats. Br J Cancer 83: 1532-1537, 2000.
26. Duthie SJ, Narayanan S, Brand GM, Pirie L and Grant G: Impact of folate deficiency on DNA stability. J Nutr 132 (8 Suppl): 2444S-2449S, 2002.
27. Butterworth CE Jr: Effect of folate on cervical cancer. Synergism among risk factors. Ann N Y Acad Sci 669: 293-299, 1992.
28. Mason JB and Levesque T: Folate: Effects on carcinogenesis and the potential for cancer chemoprevention. Oncology (Williston Park) 10: 1727-1736, 1742-1744, 1996.
29. Murakami Y: Functional cloning of a tumor suppressor gene, TSLC1, in human non-small cell lung cancer. Oncogene 21: 6936-6948, 2002.
30. Fukami T, Fukuhara H, Kuramochi M, Maruyama T, Isogai K, Sakamoto M, Takamoto S and Murakami Y: Promoter methylation of the TSLC1 gene in advanced lung tumors and various cancer cell lines. Int J Cancer 107: 53-59, 2003.